U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681479) titled 'A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants' on June 23.
Brief Summary: This study is a single-center, open-label, single-dose phase I clinical trial. The trial is divided into four periods: screening, baseline, treatment, and follow-up
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Fluid Retention Due to Heart Failure
Intervention:
DRUG: [14C]HRS-9057
[14C]HRS-9057
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....